Early Response to Saxenda® Resulted in Weight Maintenance and Additional Weight Loss Over 56 Weeks (2)

Publicado 17/05/2017 16:35:36CET

8. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-1096.

9. Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732.

10. WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en Last accessed: May 2017.

11. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669.

12. Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0?mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial. International Journal of Obesity. 2016; 40:1310-1319.

13. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. Journal of the American Medical Association. 2015; 314:687-699.

14. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373:11-22.

15. le Roux C, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. 2017; (published online Feb 22.) http://dx.doi.org/10.1016/S0140-6736(17)30069-7.

16. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013; 37:1443-1451.

  Further information   Media:     Katrine Sperling  +45-4442-6718  krsp@novonordisk.com     Asa Josefsson  +45-3079-7708  aajf@novonordisk.com   Investors:   Peter Hugreffe Ankersen  +45-3075-9085  phak@novonordisk.com   Anders Mikkelsen  +45-3079-4461  armk@novonordisk.com   Hanna Ogren  +45-3079-8519  haoe@novonordisk.com   Kasper Veje (US)  +1-609-235-8567  kpvj@novonordisk.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies